SCHEMBL2748893

SCHEMBL2748893

CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4ccccc4s3)c2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 4/20 0.64
CDK1 P06493 3/20 0.64
CDK2 P24941 3/20 0.64
MKNK1 Q9BUB5 3/20 0.64
FYN P06241 5/20 0.48
CHEK2 O96017 1/20 0.46
MAP4K4 O95819 3/20 0.46
CYP3A4 P08684 1/20 0.43
MAP4K1 Q92918 1/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
GAA P10253 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2750714 0.90 CHEK2 (0.55) MKNK2CDK1CDK2MKNK1CHEK2
SCHEMBL2750376 0.89 ATR (0.54) MKNK2CDK1CDK2MKNK1FYN
SCHEMBL2747422 0.89 MAP4K4 (0.58) MKNK2CDK1CDK2MKNK1FYN
SCHEMBL2750253 0.88 FYN (0.54) MKNK2CDK1CDK2MKNK1FYN
SCHEMBL2748849 0.87 CDK8 (0.50) MKNK2CDK1CDK2MKNK1FYN
SCHEMBL2747417 0.86 CDK8 (0.49) MKNK2CDK1CDK2MKNK1FYN
SCHEMBL2748635 0.85 CDK1 (0.48) MKNK2CDK1CDK2MKNK1FYN
SCHEMBL2749569 0.85 MKNK1 (0.48) MKNK2CDK1CDK2MKNK1FYN
SCHEMBL2748906 0.84 PRKD3 (0.62) MKNK2CDK1CDK2MKNK1FYN
SCHEMBL2749700 0.82 ATR (0.52) FYNMAP4K4ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 MKNK2 142/4885CDK1 298/4885CDK2 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.